Personalized Pemafibrate Dosing Regimens with OATP1B Inhibitor Co-administration Consideration

The present invention provides an innovative approach to optimize pemafibrate dosing regimens by integrating OATP1B inhibitor co-administration status, ensuring safer and more efficient treatment of dyslipidemia.

The original pemafibrate dosing regimens patent (Patent Literature 1) has limitations in addressing the impact of OATP1B inhibitors on pemafibrate pharmacokinetics, leading to potential adverse effects and suboptimal treatment outcomes. The present invention addresses this limitation by incorporating OATP1B inhibitor co-administration status into the dosing regimen optimization process.

The inventive concept comprises a system and method for optimizing pemafibrate dosing regimens, which takes into account the patient's original daily dose and OATP1B inhibitor co-administration status. The system utilizes a dosing calculator module, a database of OATP1B inhibitors, and a patient data input module to determine an adjusted daily dose of pemafibrate. The method involves identifying the patient's OATP1B inhibitor co-administration status and adjusting the pemafibrate dosing regimen accordingly, using a pharmacokinetic model to minimize the risk of adverse effects.

The new claims introduce the novel concept of integrating OATP1B inhibitor co-administration status into pemafibrate dosing regimen optimization, which is not disclosed in the original patent. This inventive step provides a more personalized and efficient approach to treating dyslipidemia, distinguishing the present invention from the prior art.

Alternative embodiments of the inventive concept may include different types of OATP1B inhibitors, various pharmacokinetic models, and diverse patient data input modules. Additionally, the system and method could be adapted for use with other medications affected by OATP1B inhibitors, expanding the scope of the inventive concept.

The present invention has significant commercial potential in the pharmaceutical industry, particularly in the treatment of dyslipidemia. The innovative approach to pemafibrate dosing regimen optimization could lead to improved treatment outcomes, reduced adverse effects, and enhanced patient safety, ultimately increasing market share and revenue for pharmaceutical companies.